Consistent Results Across All Sub-Groups Seen in the Newly Launched First in Class LAG-3 Combination Drug Opdualag

LAG-3 combination drug Opdualag: ASCO 2022 Bristol Myers Squibb presented a subgroup analysis from the RELATIVITY-047 trial for the newly approved OPDUALAG for the unresectable or metastatic melanoma patients. Nivolumab Mechanism of Action: Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants Recently, FDA approved Opdualag, a fixed-dose combination of nivolumab and relatlimab for patients with previously untreated melanoma that cannot be removed surgically or has spread (metastasized) within the body. The Opdualag FDA approval was based on results from a large Phase II/III clinical trial ( RELATIVITY-047). The clinical trial results have shown that Opdualag can double the time patients with previously untreated advanced melanoma can live without disease progression compared to Opdivo alone (the current SoC) without any added safety concerns. Further Exploratory analyses by pre-specified...